EXCLUSIVE LICENSE AGREEMENT FOR TPI-287 BetweenExclusive License Agreement • July 30th, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement for TPI-287 (the “Agreement”), effective as of July 29, 2024 (the “Effective Date”), is entered into by and between Cortice Biosciences, Inc., a corporation duly organized and existing under the laws of the state of Delaware having a place of business at 1345 Avenue of the Americas, 42nd floor, New York, NY 10105 (the “Licensor”) and CNS Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the state of Delaware having a place of business at 2100 West Loop South, Suite 900, Houston, Texas 77027 (“Company”). Each of Licensor and the Company may be referred to herein individually as a “Party”, and collectively as the “Parties”.
STOCK PURCHASE AGREEMENT Between CNS PHARMACEUTICALS, INC., AND CORTICE BIOSCIENCES, INC., Dated: July 29, 2024Stock Purchase Agreement • July 30th, 2024 • CNS Pharmaceuticals, Inc. • Pharmaceutical preparations
